149 related articles for article (PubMed ID: 33628778)
1. Chemoradiotherapy and Increased Prescription Dose in Esophageal Squamous Cell Cancer: A Retrospective Study.
Pan X; Liao M; Ma H; Jiang X; Huang H; Wei M; Li Q
Biomed Res Int; 2021; 2021():3834040. PubMed ID: 33628778
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
[No Abstract] [Full Text] [Related]
3. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy analysis of the radiotherapy and chemotherapy in patients with stage Ⅳ esophageal squamous carcinoma: a multicenter retrospective study of Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG R-01F)].
Hu MM; Yuan QQ; Zhang XS; Yang S; Wang X; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Pang QS; Zhao YD; Sun XC; Li GF; Li L; Qiao XY; Liu ML; Wang YD; Li C; Zhu SC; Han C; Zhang KX; Xiao ZF
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):676-681. PubMed ID: 32867461
[No Abstract] [Full Text] [Related]
5. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience.
Xu Y; Wang Z; Liu G; Zheng X; Wang Y; Feng W; Lai X; Zhou X; Li P; Ma H; Wang J; Hu X; Chen M
J Cancer Res Ther; 2016 Oct; 12(Supplement):82-88. PubMed ID: 27721262
[TBL] [Abstract][Full Text] [Related]
6. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Zhu H; Rivin Del Campo E; Ye J; Simone CB; Zhu Z; Zhao W; Amini A; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Mo M; Jia H; Lu S; Wang J; Nie Y; Chen J; Wu S; Hamaji M; Haque W; Jeong BK; Shridhar R; Zhang Z; Chen Y; Zhao K
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1396-1406. PubMed ID: 33677048
[TBL] [Abstract][Full Text] [Related]
7. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy.
Pao TH; Chang WL; Chiang NJ; Chang JS; Lin CY; Lai WW; Tseng YL; Yen YT; Chung TJ; Lin FC
Radiat Oncol; 2020 Sep; 15(1):221. PubMed ID: 32962730
[TBL] [Abstract][Full Text] [Related]
8. Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer.
Nakatani Y; Kato K; Shoji H; Iwasa S; Honma Y; Takashima A; Ushijima T; Ito Y; Itami J; Boku N
Int J Clin Oncol; 2020 Jun; 25(6):1098-1104. PubMed ID: 32189155
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma: A single institution experience.
Ke TM; Fong Y; Lin LC; Chien YW; Yang CC; Lin CH; Lin KL; Que J
Medicine (Baltimore); 2018 Nov; 97(46):e13214. PubMed ID: 30431596
[TBL] [Abstract][Full Text] [Related]
10. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
Ren XJ; Wang L; Han C; Liu LL
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
[No Abstract] [Full Text] [Related]
12. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
[TBL] [Abstract][Full Text] [Related]
13. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma.
Lertbutsayanukul C; Tharavej C; Klaikeaw N; Prayongrat A; Lowanitchai C; Sriuranpong V
Thorac Cancer; 2017 May; 8(3):219-228. PubMed ID: 28322515
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy.
Xu X; Wang Z; Jiang S; Shang Y; Wu Y
Radiat Oncol; 2019 Nov; 14(1):191. PubMed ID: 31684983
[TBL] [Abstract][Full Text] [Related]
15. A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.
Wu X; Hu X; Chen J; He L
Radiat Oncol; 2021 Jun; 16(1):100. PubMed ID: 34103059
[TBL] [Abstract][Full Text] [Related]
16. Stricture rate after chemoradiotherapy and radiotherapy for oesophageal squamous cell carcinoma: a 20-year experience.
Hamer PW; Hight SC; Ward IG; Harris DL; Woodham BL; Flint RS
ANZ J Surg; 2019 Apr; 89(4):367-371. PubMed ID: 30791194
[TBL] [Abstract][Full Text] [Related]
17. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
Dreyfuss AD; Barsky AR; Wileyto EP; Eads JR; Kucharczuk JC; Williams NN; Karasic TB; Metz JM; Ben-Josef E; Plastaras JP; Wojcieszynski AP
Cancer Med; 2021 Feb; 10(4):1275-1288. PubMed ID: 33474812
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
Pöttgen C; Gkika E; Stahl M; Abu Jawad J; Gauler T; Kasper S; Trarbach T; Herrmann K; Lehmann N; Jöckel KH; Lax H; Stuschke M
Radiat Oncol; 2021 Mar; 16(1):59. PubMed ID: 33757534
[TBL] [Abstract][Full Text] [Related]
20. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
